Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Gamida Cell Ltd. (GMDA : NSDQ)
 
 • Company Description   
Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel.

Number of Employees: 168

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.36 Daily Weekly Monthly
20 Day Moving Average: 1,642,866 shares
Shares Outstanding: 59.20 (millions)
Market Capitalization: $139.71 (millions)
Beta: 1.82
52 Week High: $6.94
52 Week Low: $2.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.32% -18.17%
12 Week -30.18% -24.24%
Year To Date -7.09% 10.49%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
116 Huntington Avenue
-
Boston,MA 02116
ISR
ph: 713-400-6400
fax: -
irpr@gamida-cell.com http://www.gamida-cell.com
 
 • General Corporate Information   
Officers
Julian Adams - Director and Chief Executive Officer
Robert I. Blum - Chairman
Michele Korfin - Chief Operating and Chief Commercial Officer
Shai Lankry - Chief Financial Officer
Josh Patterson - General Counsel and Chief Compliance Officer

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M47364100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 59.20
Most Recent Split Date: (:1)
Beta: 1.82
Market Capitalization: $139.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.59
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -205.58
12/31/21 - -150.99
09/30/21 - -113.08
ROA
03/31/22 - -58.85
12/31/21 - -50.83
09/30/21 - -50.97
Current Ratio
03/31/22 - 3.55
12/31/21 - 3.88
09/30/21 - 5.22
Quick Ratio
03/31/22 - 3.55
12/31/21 - 3.88
09/30/21 - 5.22
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.42
12/31/21 - 0.74
09/30/21 - 0.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 2.87
12/31/21 - 1.63
09/30/21 - 1.51
Debt-to-Capital
03/31/22 - 74.13
12/31/21 - 61.91
09/30/21 - 60.13
 

Powered by Zacks Investment Research ©